JPWO2021216972A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021216972A5 JPWO2021216972A5 JP2022564276A JP2022564276A JPWO2021216972A5 JP WO2021216972 A5 JPWO2021216972 A5 JP WO2021216972A5 JP 2022564276 A JP2022564276 A JP 2022564276A JP 2022564276 A JP2022564276 A JP 2022564276A JP WO2021216972 A5 JPWO2021216972 A5 JP WO2021216972A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- antibody
- cancer
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063015149P | 2020-04-24 | 2020-04-24 | |
| US63/015,149 | 2020-04-24 | ||
| PCT/US2021/028798 WO2021216972A1 (en) | 2020-04-24 | 2021-04-23 | Anti-cd3 antibodies and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023523584A JP2023523584A (ja) | 2023-06-06 |
| JPWO2021216972A5 true JPWO2021216972A5 (https=) | 2024-05-02 |
| JP2023523584A5 JP2023523584A5 (https=) | 2024-05-02 |
| JP7791836B2 JP7791836B2 (ja) | 2025-12-24 |
Family
ID=78270196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564276A Active JP7791836B2 (ja) | 2020-04-24 | 2021-04-23 | 抗ｃｄ３抗体及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230212289A1 (https=) |
| EP (1) | EP4139347A4 (https=) |
| JP (1) | JP7791836B2 (https=) |
| CN (1) | CN115803340A (https=) |
| CA (1) | CA3176391A1 (https=) |
| WO (1) | WO2021216972A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US11912771B2 (en) | 2021-03-09 | 2024-02-27 | Cdr-Life Ag | MAGE-A4 peptide-MHC antigen binding proteins |
| EP4304725A1 (en) | 2021-03-09 | 2024-01-17 | CDR-Life AG | Rabbit-derived antigen binding protein nucleic acid libraries |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| WO2023205733A1 (en) * | 2022-04-21 | 2023-10-26 | Academia Sinica | Genetically engineered innate lymphoid cells for enhancing lifespan and/or treating cancers |
| US20260042860A1 (en) * | 2022-08-04 | 2026-02-12 | Memorial Sloan-Kettering Cancer Center | Anti-cd24 antibodies and uses thereof |
| KR20250067130A (ko) | 2022-09-14 | 2025-05-14 | 씨디알-라이프 아게 | Mage-a4 펩티드 이중 t 세포 연결체 |
| WO2024199454A1 (en) * | 2023-03-29 | 2024-10-03 | Nanjing GenScript Biotech Co., Ltd. | Antibodies and variants thereof against human cluster of differentiation 3 protein |
| CN116574182B (zh) * | 2023-06-09 | 2024-02-06 | 上海交通大学医学院附属第九人民医院 | 一种抗人Ki-67抗体及其制备方法和用途 |
| CN121293363B (zh) * | 2025-12-09 | 2026-04-21 | 上海玄言生物科技有限公司 | 一种靶向cd14和cd3的双功能t细胞衔接器及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0720565A2 (pt) * | 2006-12-20 | 2013-09-17 | Mmr Information Systems Inc | anticorpos e mÉtodos para a sua preparaÇço e seu uso |
| CN102796199A (zh) * | 2011-05-26 | 2012-11-28 | 中国医学科学院血液病医院 | 抗CD3抗体Fv片段与白介素3融合蛋白突变体、制备方法及其用途 |
| EP2892924B1 (en) * | 2012-06-14 | 2020-11-25 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
| CN103173478B (zh) * | 2013-03-04 | 2015-09-09 | 西北大学 | 一种携带ptd的抗人cd3单链抗体的制备方法 |
| CN103467605B (zh) * | 2013-09-05 | 2015-02-04 | 武汉友芝友生物制药有限公司 | 一种cd3抗原及其制备方法和用途 |
| US20160326249A1 (en) * | 2014-01-15 | 2016-11-10 | Zymeworks Inc. | Bi-specific cd3 and cd19 antigen-binding constructs |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| RU2020122439A (ru) * | 2014-11-24 | 2020-09-24 | Регенерон Фармасьютикалз, Инк. | Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3 |
| US11046768B2 (en) | 2017-01-27 | 2021-06-29 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| KR20190140943A (ko) * | 2017-04-24 | 2019-12-20 | 메모리얼 슬로안 케터링 캔서 센터 | 항-cd33 항체 제제 |
| US20180371088A1 (en) * | 2017-06-22 | 2018-12-27 | Development Center For Biotechnology | TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY |
| MX2020009774A (es) * | 2018-03-21 | 2020-10-08 | Alx Oncology Inc | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. |
| EP3802595A1 (en) * | 2018-06-07 | 2021-04-14 | OncoOne Research & Development GmbH | Anti-oxmif/anti-cd3 antibody for cancer treatment |
| WO2020062155A1 (en) | 2018-09-29 | 2020-04-02 | Mab-Legend Biotech Co., Ltd. | Dual targeting antigen binding molecule |
| CN110964114B (zh) | 2018-09-29 | 2023-07-04 | 上海博槿生物科技有限公司 | 一种双靶点抗原结合分子 |
-
2021
- 2021-04-23 CN CN202180043797.1A patent/CN115803340A/zh active Pending
- 2021-04-23 JP JP2022564276A patent/JP7791836B2/ja active Active
- 2021-04-23 EP EP21792369.7A patent/EP4139347A4/en active Pending
- 2021-04-23 US US17/920,539 patent/US20230212289A1/en active Pending
- 2021-04-23 CA CA3176391A patent/CA3176391A1/en active Pending
- 2021-04-23 WO PCT/US2021/028798 patent/WO2021216972A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bacac et al. | A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors | |
| Wei et al. | ImmunoPET: concept, design, and applications | |
| Mandikian et al. | Relative target affinities of T-cell–dependent bispecific antibodies determine biodistribution in a solid tumor mouse model | |
| Hernandez-Hoyos et al. | MOR209/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer | |
| Dorff et al. | Novel redirected T–cell immunotherapies for advanced prostate cancer | |
| Scott et al. | Antibody therapy of cancer | |
| Han et al. | The old CEACAMs find their new role in tumor immunotherapy | |
| Welt et al. | Phase I study of anticolon cancer humanized antibody A33 | |
| De Pauw et al. | Current status and future expectations of nanobodies in oncology trials | |
| Cao et al. | Bispecific antibodies as novel bioconjugates | |
| JP2021503927A5 (https=) | ||
| Cheal et al. | Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma | |
| Navarro-Teulon et al. | General overview of radioimmunotherapy of solid tumors | |
| JP2020523029A5 (https=) | ||
| Chester et al. | Engineering antibodies for clinical applications in cancer | |
| IL273484B1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| Abousaway et al. | Noninvasive imaging of cancer immunotherapy | |
| JPWO2021216972A5 (https=) | ||
| Guo et al. | Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment | |
| Bogen et al. | Treating bladder cancer: Engineering of current and next generation antibody-, fusion protein-, mRNA-, cell-and viral-based therapeutics | |
| Lin et al. | The evolution of antibodies into versatile tumor-targeting agents | |
| van Winkel et al. | Molecular imaging supports the development of multispecific cancer antibodies | |
| JP2021517816A5 (https=) | ||
| Lo et al. | Anti-LYPD1/CD3 T-cell-dependent bispecific antibody for the treatment of ovarian cancer | |
| Plüss et al. | Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen |